Scilex Holding Company Receives FDA Approval for Commercial Manufacturing of Gloperba, a Revolutionary Treatment for Painful Gout Flares
PALO ALTO, Calif. June 6, 2024 - Scilex Holding Company (Nasdaq: SCLX), a leading innovator in the field of non-opioid pain management, announced today the approval by the U.S. Food and Drug Administration (FDA) for the commercial manufacturing of Gloperba. This groundbreaking prophylactic treatment for painful gout flares in adults marks an important milestone in the fight against chronic pain. The product will be launched in the United States during the week of June 10th, 2024.
Gloperba is the result of extensive research and development efforts aimed at addressing the urgent need for effective non-opioid pain management solutions. Scilex is dedicated to acquiring, developing, and commercializing products that offer alternatives to opioids, and this FDA approval is a significant step forward in fulfilling that mission.
Gout, a form of arthritis, affects millions of individuals worldwide, causing excruciatingly painful flares that can severely impact a person’s quality of life. Traditional treatment options often involve the use of nonsteroidal anti-inflammatory drugs (NSAIDs) or oral steroids, which may have adverse side effects and limited efficacy.
However, Gloperba is set to revolutionize gout management. Its prophylactic approach means that patients will no longer have to wait until a gout flare occurs to seek treatment. By taking Gloperba regularly, individuals can significantly reduce the frequency and severity of flare-ups, providing long-term relief and preventing the debilitating pain associated with gout.
Scilex plans to immediately stock Gloperba in all major wholesalers and pharmacies across the country. The widespread availability of this innovative treatment will provide physicians and patients with a much-needed alternative to traditional pain management approaches.
The approval of commercial manufacturing for Gloperba is a testament to Scilex’s commitment to innovation and patient-centric care. By expanding the range of non-opioid options available to physicians, the company is playing a crucial role in combating the opioid crisis and improving patients’ lives.
Scilex’s dedication to scientific excellence and innovation is reflected in its extensive portfolio of pain management products. The FDA approval of Gloperba represents just one of many advancements the company has made in providing effective and safe alternatives to opioids.
As the launch date of Gloperba approaches, patients and healthcare professionals alike can look forward to a new era of gout management. With this exciting development, Scilex is demonstrating its commitment to improving the lives of those affected by chronic pain and ensuring a brighter future for pain management.
Comments